1. Home
  2. PACK vs RLMD Comparison

PACK vs RLMD Comparison

Compare PACK & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ranpak Holdings Corp

PACK

Ranpak Holdings Corp

HOLD

Current Price

$3.82

Market Cap

303.3M

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$7.22

Market Cap

319.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PACK
RLMD
Founded
1972
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
303.3M
319.7M
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
PACK
RLMD
Price
$3.82
$7.22
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$6.50
$12.40
AVG Volume (30 Days)
448.3K
1.3M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
$395,000,000.00
$13,070.00
Revenue This Year
$9.29
N/A
Revenue Next Year
$8.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.08
154.83
52 Week Low
$2.91
$0.27
52 Week High
$6.31
$7.65

Technical Indicators

Market Signals
Indicator
PACK
RLMD
Relative Strength Index (RSI) 48.14 63.70
Support Level $3.36 $3.49
Resistance Level $5.78 $7.41
Average True Range (ATR) 0.17 0.44
MACD 0.10 0.02
Stochastic Oscillator 80.53 72.12

Price Performance

Historical Comparison
PACK
RLMD

About PACK Ranpak Holdings Corp

Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Share on Social Networks: